ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy
ABSTRACT Background Neoadjuvant chemoimmunotherapy has achieved high downstaging and pathologic response rates in nonsmall‐cell lung cancer (NSCLC), but outcomes vary significantly. Early identification of beneficiaries remains a challenge. Methods This study analyzed baseline transcriptomic data fr...
Saved in:
| Main Authors: | Chao He, Rui Han, Taiming Zhang, Peng Zhong, Daijuan Huang, Conghua Lu, Yimin Zhang, Jianghua Li, Yuwen Deng, Yong He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70056 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study
by: Shuhan Xie, et al.
Published: (2025-07-01) -
CT-based habitat radiomics for predicting treatment response to neoadjuvant chemoimmunotherapy in esophageal cancer patients
by: Weibo Kong, et al.
Published: (2024-12-01) -
Antibiotic Use and Survival in Patients With Late-Stage NSCLC Treated With Chemoimmunotherapy
by: Emanuela Taioli, MD, PhD, et al.
Published: (2024-12-01) -
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
by: Belén Sierra Rodero, et al.
Published: (2025-12-01) -
Comparison of neoadjuvant chemoimmunotherapy with planned surgery and concurrent chemoradiation followed by immunotherapy for potentially resectable stage III non-small-cell lung cancer: a retrospective study
by: Yana Qi, et al.
Published: (2025-02-01)